Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Copy Paste From - CEO.ca

<< Previous

Bullboard Posts

Next >>

Post by Goldnboy1on Jul 03, 2023 8:00pm

511 Views

Post# 35525231

Copy Paste From - CEO.ca

 	Colorectal results will be released at ESMO in Spain in October. If we get a hit there is basically like a base hit now versus a home run hit out of the park. In my opinion anyway. The company repeating the CAR-T results that gave us 7/7 cures in mice at Mayo could have results anytime too. Company name is under a non-disclosure agreement for now. A hit there could open up the solid tumor market to CAR-T. No telling how high that could take us.